Current screening guidelines may prevent early diagnosis of lung cancer in many cases, according to research presented at the American Association for Thoracic Surgery (AATS) Annual Meeting. In a study of nearly 1200 patients who underwent lung cancer surgery,…
Brief summary: The recent study “Standardization of Reporting for Incidental Findings in Lung Cancer Screening,” published in the Journal of the American College of Radiology, supports a more standardized approach to incidental findings (IFs) in lung cancer screenings. This…
Doctors, scientists and researchers have built an artificial intelligence model that can accurately identify cancer in a development they say could speed up diagnosis of the disease and fast-track patients to treatment. Cancer is a leading cause of death…
ABSTRACT SUMMARY Researchers have created a deep learning model called Sybil. Sybil predicts a person’s future lung cancer risk from a single low-dose chest CT scan. The model is very accurate, even without extra information like age or medical…
ICB therapy, which stands for immune checkpoint blockade, has become the standard treatment for lung cancer due to its generally positive outcomes. Thus far, high levels of the PD-L1 protein have been the primary means of predicting a positive…
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III…
Patients with moderate to severe depression may have elevated inflammatory biomarkers shown to predict survival in lung cancer, according to recent study results. Both lung cancer and depression have properties of inflammation, which is the body’s response to injury…
Results from the first long-term study of how lung cancer evolves has been published in the journals Nature and Nature Medicine, with the researchers hoping the findings could help predict how a patient’s tumor will spread and enable them…
Rates of lung cancer screening with low-dose CT (LDCT) were extremely low among eligible patients across insurance types in 2017, with rates varying between patient demographics, according to a study published in Journal of the American College of Radiology.1…
The National Cancer Institute (NCI) launched the phase 3 Pragmatica-Lung Study (S2302) clinical trial evaluating Cyramza (ramucirumab) plus Keytruda (pembrolizumab) for patients with stage 3 or recurrent non-small cell lung cancer, according to a press release from the agency.…